Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > they should give us details re milestones for funding AND

<< Previous

Bullboard Posts

Next >>

Post by edroseon Jun 11, 2020 12:25pm

96 Views

Post# 31138982

they should give us details re milestones for funding AND

THEY SAY KLY AS TO PAY SALZMAN 29 MILLION AND SEPERATE 5 MILLION RE MILESTONES THIS IS ON TOP OF GIVING SALZMAN 49% OF KLY TO SALZMAN

IR PERSON AS WELL AS CEO AND BOARD WILL ONCE AGAIN NOT RELEASE THIS INFORMATION AND ASK US TO VOTE BLINDLY

WHAT % OF SALES WILL GO TO KLY VERSUS SALZMAN I BET KLY WILL ONLY GET VERY SMALL % OF REVENUES

<< Previous

Bullboard Posts

Next >>

Southern Ontario mineral processing operation receives green fund support